2020
Hypertension and kidney disease progression.
Rigo D, Orias M. Hypertension and kidney disease progression. Clinical Nephrology 2020, 93: 103-107. PMID: 31549630, DOI: 10.5414/cnp92s118.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney disease progressionDisease progressionCases of CKDHypertension-attributed nephropathyRisk of progressionAfrican American patientsGene risk variantsClinical suspicionHypertensive nephropathyKidney diseaseUnknown etiologyCommon findingProgressionHypertensionNephropathyPatientsRisk variantsGenetic backgroundEtiologyDiseaseDiagnosisSuspicion
2014
Estimated GFR or Albuminuria: Which One Is Really Associated With Resistant Hypertension?
Romero CA, Peixoto AJ, Orias M. Estimated GFR or Albuminuria: Which One Is Really Associated With Resistant Hypertension? Seminars In Nephrology 2014, 34: 492-497. PMID: 25416657, DOI: 10.1016/j.semnephrol.2014.08.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLow estimated glomerular filtration rateEstimated glomerular filtration rateResistant hypertensionGlomerular filtration rateFiltration rateHigh cardiovascular risk groupTarget organ damageComplications of hypertensionCardiovascular risk groupsHigher sympathetic activityEndothelial dysfunctionFluid overloadSympathetic activityOrgan damageKidney diseaseRisk groupsHigh prevalenceHypertensionMicroalbuminuriaPrevalenceDifferent phenotypesPhenotypeAlbuminuriaComplicationsGFR
2013
Does Kidney Disease Cause Hypertension?
Peixoto AJ, Orias M, Desir GV. Does Kidney Disease Cause Hypertension? Current Hypertension Reports 2013, 15: 89-94. PMID: 23344662, DOI: 10.1007/s11906-013-0327-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseRenal functionStructural kidney diseaseGlomerular filtration ratePlasmin-mediated activationExtracellular fluid volumeProteinuric glomerular diseasesPolycystic kidney diseaseChronic hypertensionHypertension increasesEpithelial sodium channelSodium retentionFiltration rateGlomerular diseaseHypertensionCurrent evidenceDiseaseSodium channelsFluid volumeDetectable changeSevere reductionMost casesProteinuriaPatients
2012
A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation.
H Mukdsi J, Gutiérrez S, Barrón B, Novoa P, Fernández S, de Diller AB, I Torres A, Formica RN, Orías M. A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation. Journal Of Nephropathology 2012, 1: 194-7. PMID: 24475416, PMCID: PMC3886146, DOI: 10.5812/nephropathol.8123.Peer-Reviewed Case Reports and Technical NotesFabry diseaseRenal variantLong-term followProgressive kidney diseaseYear old manEnzyme replacement therapyΑ-GalA activityRecessive inborn errorPodocyte activationSecond biopsySystemic manifestationsKidney diseaseReplacement therapyHistologic dataDirect DNA sequencingGenetic testingDeficient activityDiseaseElectron microscopic evidenceInborn errorsTherapy treatmentGlycosphingolipid metabolismGene mutationsHemizygote mutationIntracellular inclusions
2009
Is there a role for direct renin inhibitors in chronic kidney disease?
Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Current Opinion In Nephrology & Hypertension 2009, 18: 397-403. PMID: 19584722, DOI: 10.1097/mnh.0b013e32832e3183.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseBlood pressure controlKidney disease progressionRenin inhibitorsCardiovascular eventsKidney diseaseDisease progressionEffective blood pressure controlPressure controlHard renal endpointsEarly diabetic nephropathyNormal renal functionDirect renin inhibitorRandomized clinical trialsRenal endpointsStudy drugCardiovascular riskDiabetic nephropathyRenal functionRenal injuryImproved survivalClinical trialsAnimal modelsHuman studiesPatientsAliskiren and the Kidney: Beyond Hypertension
Trimarchi H, Orías M. Aliskiren and the Kidney: Beyond Hypertension. Nephrology Research & Reviews 2009, 1: 1-4. DOI: 10.4081/nr.2009.e1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPlasma renin activityRenin activityReceptor blockersGlomerular diseaseRenin angiotensin aldosterone systemAldosterone receptor blockersEndstage kidney diseaseAngiotensin aldosterone systemAngiotensin receptor blockersRenal disease progressionSecondary glomerular diseasesUse of angiotensinRenin-angiotensin systemUrinary protein excretionNew therapeutic optionsDiabetic nephropathyProtein excretionKidney diseaseTherapeutic optionsDisease progressionComplete blockadeUrinary proteinSide effectsEnzyme inhibitorsImportant cause